A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

医学 内科学 肝细胞癌 危险系数 肿瘤科 阿替唑单抗 免疫疗法 队列 比例危险模型 荟萃分析 不利影响 癌症 置信区间 无容量
作者
Lorenz Balcar,Bernhard Scheiner,Claudia Angela Maria Fulgenzi,Antonio D’Alessio,Katharina Pomej,Marta Bofill Roig,Elias Laurin Meyer,Jaekyung Cheon,Naoshi Nishida,Pei‐Chang Lee,Linda Y. Wu,Celina Ang,Anja Krall,Anwaar Saeed,Bernardo Stefanini,Antonella Cammarota,Tiziana Pressiani,Yehia I. Abugabal,Shadi Chamseddine,Brooke Wietharn,Alessandro Parisi,Yi Hsiang Huang,Samuel Phen,Caterina Vivaldi,Francesca Salani,Gianluca Masi,Dominik Bettinger,Arndt Vogel,Johann von Felden,Kornelius Schulze,Marianna Silletta,Michael Trauner,Adel Samson,Henning Wege,Fabio Piscaglia,Peter R. Galle,Rudolf Stauber,Masatoshi Kudo,Amit G. Singal,Aleena Itani,Susanna V. Ulahannan,Neehar D. Parikh,Alessio Cortellini,Ahmed O. Kaseb,Lorenza Rimassa,Hong Jae Chon,David J. Pinato,Matthias Pinter
出处
期刊:JHEP reports [Elsevier BV]
卷期号:6 (2): 100982-100982 被引量:1
标识
DOI:10.1016/j.jhepr.2023.100982
摘要

Sex-related differences in the immune pathogenesis of hepatocellular carcinoma (HCC), particularly related to oestrogen-dependent secretion of pro-tumourigenic cytokines, are well-known. Whether sex influences the efficacy and safety of immunotherapy is not known.We performed a restricted maximum likelihood random effects meta-analysis of five phase III trials that evaluated immune checkpoint inhibitors (ICIs) in advanced HCC and reported overall survival (OS) hazard ratios (HRs) stratified by sex to evaluate sex-related differences in OS. In a real-world cohort of 840 patients with HCC from 22 centres included between 2018 and 2023, we directly compared the efficacy and safety of atezolizumab + bevacizumab (A+B) between sexes. Radiological response was reported according to RECIST v1.1. Uni- and multivariable Cox regression analyses were performed for OS and progression-free survival (PFS).In the meta-analysis, immunotherapy was associated with a significant OS benefit only in male (pooled HR 0.79; 95% CI 0.73-0.86) but not in female (pooled HR 0.85; 95% CI 0.70-1.03) patients with HCC. When directly comparing model estimates, no differences in the treatment effect between sexes were observed. Among 840 patients, 677 (81%) were male (mean age 66 ± 11 years), and 163 (19%) were female (mean age 67 ± 12 years). Type and severity of adverse events were similar between the two groups. OS and PFS were comparable between males and females upon uni- and multivariable analyses (aHR for OS and PFS: 0.79, 95% CI 0.59-1.04; 1.02, 95% CI 0.80-1.30, respectively). Objective response rates (24%/22%) and disease control rates (59%/59%) were also similar between sexes.Female phase III trial participants experienced smaller OS benefit following ICI therapy for advanced HCC, while outcomes following A+B treatment were comparable between sexes in a large real-world database. Based on the ambiguous sex-related differences in survival observed here, further investigation of sex-specific clinical and biologic determinants of responsiveness and survival following ICIs are warranted.While immune checkpoint inhibitors have emerged as standard of care for the treatment of hepatocellular carcinoma, there are conflicting reports on whether the efficacy of cancer immunotherapy differs between females and males. Our study suggests ambiguous sex-related differences in outcomes from immunotherapy in hepatocellular carcinoma. Further investigation of sex-specific clustering in clinicopathologic and immunologic determinants of responsiveness to immune checkpoint inhibitor therapy should be prioritised.PROSPERO CRD42023429625.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
heli发布了新的文献求助10
刚刚
1秒前
猪猪hero发布了新的文献求助10
1秒前
打打应助哈哈鹿采纳,获得10
2秒前
skye完成签到,获得积分10
2秒前
CipherSage应助义气如萱采纳,获得10
2秒前
zty发布了新的文献求助30
2秒前
SS发布了新的文献求助10
2秒前
戴岱发布了新的文献求助10
4秒前
6秒前
量子星尘发布了新的文献求助10
8秒前
9秒前
张大英发布了新的文献求助10
11秒前
马er完成签到,获得积分20
11秒前
奮斗完成签到,获得积分10
11秒前
戴岱完成签到,获得积分10
12秒前
哈哈鹿发布了新的文献求助10
13秒前
13秒前
黎明森完成签到,获得积分10
13秒前
Monica应助朴素若枫采纳,获得30
14秒前
15秒前
科研通AI5应助科研通管家采纳,获得10
15秒前
SYLH应助科研通管家采纳,获得30
15秒前
15秒前
czh应助科研通管家采纳,获得10
15秒前
科研通AI2S应助科研通管家采纳,获得10
15秒前
15秒前
今后应助科研通管家采纳,获得10
15秒前
顾矜应助科研通管家采纳,获得10
15秒前
15秒前
丘比特应助科研通管家采纳,获得10
15秒前
赘婿应助科研通管家采纳,获得10
15秒前
15秒前
15秒前
15秒前
王羊补牢发布了新的文献求助10
18秒前
布施德完成签到 ,获得积分10
19秒前
Zzz完成签到,获得积分10
20秒前
呆萌板凳完成签到,获得积分20
22秒前
23秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989242
求助须知:如何正确求助?哪些是违规求助? 3531393
关于积分的说明 11253753
捐赠科研通 3270010
什么是DOI,文献DOI怎么找? 1804868
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136